Last reviewed · How we verify
SB-480848
At a glance
| Generic name | SB-480848 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Integrated Biomarker And Imaging Study - 2 (PHASE2)
- A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients (PHASE2)
- The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (PHASE3)
- A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment (PHASE1)
- Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects (PHASE1)
- Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848). (PHASE1)
- Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects (PHASE1)
- Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB-480848 CI brief — competitive landscape report
- SB-480848 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI